Visual summary
Pulmonary–renal anti-GBM disease is an emergency; complement-mediated disease requires a different diagnostic pathway.
Illustration updated October 18, 2026. Educational schematic. Imaging and microscopy panels are illustrations, not patient studies. Full teaching text and sources follow.
Diagram description
Linear antibody binding differs from complement-driven injury. . Urgent anti-GBM evaluation and a complement-pattern workup are different pathways; use serology and biopsy together. The infographic uses anatomical illustrations and integrated labels; the complete teaching text and evidence are below.
Text version
Recognize the anti-GBM emergency
Rapid creatinine rise with glomerular hematuria and possible hemoptysis/hypoxemia should prompt urgent nephrology evaluation. Pulmonary hemorrhage may occur even without striking hemoptysis.
Send time-critical tests
Obtain anti-GBM antibodies, ANCA, urinalysis/protein quantification, blood count, creatinine, and appropriate chest assessment. Arrange kidney biopsy when feasible. Strong suspicion of organ-threatening disease warrants specialist treatment decisions before every result returns.
The biopsy patterns differ
Anti-GBM disease classically produces linear IgG staining along the basement membrane. C3-dominant staining suggests a complement-mediated pattern; immune-complex deposits raise another differential. The staining pattern guides further testing.
Understand anti-GBM treatment goals
Plasma exchange removes circulating antibody; immunosuppression reduces further production and inflammation. Kidney recovery potential, dialysis dependence, biopsy damage, and pulmonary hemorrhage affect decisions; no single creatinine cutoff substitutes for specialist assessment.
Investigate a complement pattern
C3/C4 levels, infection assessment, monoclonal protein studies, and specialist complement testing help distinguish triggers and mechanisms. A low C3 alone does not prove C3 glomerulopathy or select a complement inhibitor.
Worked distinction
Hematuria and AKI with pulmonary hemorrhage needs an urgent anti-GBM/ANCA pathway. Isolated low C3 with persistent proteinuria needs a pathology-led cause search. These presentations should not share one generic immunosuppression algorithm.
